Suplemento y Tratamiento Capilar Xtressé™ para el Crecimiento del Cabello en Mujeres con Pérdida de Cabello

Fecha de inicio: 20 de mayo de 2025

Inclusion Criteria: * Female adults between 28-65 years of age with consistent self-perceived thinning hair. * Ludwig Scale I or II (mild to moderate thinning hair loss), assessed clinically. * Fitzpatrick Skin Types I to VI. * Agree to maintain their current diet, medications, exercise routines, hair shampooing, and color treatment frequency for the duration of the study. * Ability and willingness to comply with the study protocol including regular visits and product application. * Written informed consent obtained, including written consent to allow photographs to be used as part of the study data and documentation. * For females of childbearing potential, a negative pregnancy test at screening and commitment to effective contraception throughout the study (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy) to avoid pregnancy-related hormonal changes affecting hair density. Exclusion Criteria: * Pregnant or lactating or planning to become pregnant. * Changes in hormonal therapy within 6 months prior to enrollment and throughout the study. * Use of other medical hair loss treatments (e.g., Minoxidil, Dutasteride, Finasteride, laser or light therapy) within 3 months prior to study start and throughout the study. * Micro-needling, PRP, or any other physical treatment modality on the scalp (within 6 months prior to study start and throughout the study). * Use of GLP-1 inhibitors (e.g., Semaglutide) within 6 months prior to study start and throughout the study. * Known uncontrolled health conditions (e.g., thyroid disease, anemia) that could confound study outcomes. * Known sensitivity to any of the ingredients in the study medication. * In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study. * Subject has any conditions, findings in history, physical exam or laboratory assessments, which in the opinion of the investigator, would exclude the subject from continuing in this study. * Treatment with an experimental drug, biologic or device within 12 weeks of the screening visit.